Table 4.
Characteristics of vaccine and non-vaccine trials.
| Variable | Subgroup | Vaccine | Non-vaccine | χ2/Fisher | P value |
|---|---|---|---|---|---|
| (N=111) | (N=27) | ||||
| Year | 2.803* | 0.421 | |||
| Prior to 2007 | 17 (15.3%) | 6 (22.2%) | |||
| 2007–2012 | 43 (38.7%) | 7 (25.9%) | |||
| 2012–2017 | 37 (33.3%) | 12 (44.4%) | |||
| 2017–now | 14 (12.6%) | 2 (7.4%) | |||
| Status | 3.456* | 0.751 | |||
| Active, not recruiting | 11 (9.9%) | 2 (7.4%) | |||
| Completed | 85 (76.6%) | 20 (74.1%) | |||
| Recruiting | 6 (5.4%) | 2 (7.4%) | |||
| Suspended | 1 (0.9%) | 0 (0.0%) | |||
| Terminated | 2 (1.8%) | 1 (3.7%) | |||
| Unknown status | 5 (4.5%) | 1 (3.7%) | |||
| Withdrawn | 1 (0.9%) | 1 (3.7%) | |||
| Study results | 6.670 | 0.011 | |||
| Has results | 41 (36.9%) | 3 (11.1%) | |||
| No results available | 70 (63.1%) | 24 (88.9%) | |||
| Lead sponsor | 24.400* | <0.001 | |||
| University | 10 (9.0%) | 10 (37.0%) | |||
| Hospital | 7 (6.3%) | 7 (25.9%) | |||
| Industry | 84 (75.7%) | 8 (29.6%) | |||
| Other | 10 (9.0%) | 2 (7.4%) | |||
| Funded by | 22.864* | <0.001 | |||
| Industry | 79 (71.2%) | 7 (25.9%) | |||
| NIH | 6 (5.4%) | 0 (0.0%) | |||
| Other | 26 (23.4%) | 20 (74.1%) | |||
| Locations | 7.695* | 0.078 | |||
| Asia | 15 (13.5%) | 1 (3.7%) | |||
| Europe | 33 (29.7%) | 9 (33.3%) | |||
| North America | 59 (53.2%) | 14 (51.9%) | |||
| Oceania | 4 (3.6%) | 1 (3.7%) | |||
| South America | 0 (0.0%) | 2 (7.4%) | |||
| Microbial etiology | 32.107* | <0.001 | |||
| Viral | 87 (78.4%) | 11 (40.7%) | |||
| Bacterial | 24 (21.6%) | 7 (25.9%) | |||
| Parasite | 0 (0.0%) | 1 (3.7%) | |||
| Unknown | 0 (0.0%) | 8 (29.6%) | |||
*Fisher exact test.